ArticleFrontiers in medicine2026
Impact of Yuehua Decoction on quality of life and safety in multidrug-resistant tuberculosis: a prospective cohort study using multivariable regression analysis.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Multidrug-resistant tuberculosis (MDR-TB) remains a major global health challenge, and prolonged chemotherapy often leads to substantial symptom burden and impaired health-related quality of life (HRQoL). Host-directed adjunctive therapies, including Traditional Chinese Medicine, have received growing interest; however, prospective clinical evidence on Yuehua Decoction remains limited. This study evaluated whether adjunctive Yuehua Decoction improves HRQoL and safety among patients receiving standardized MDR-TB treatment. Methods: We conducted a prospective, non-randomized cohort study enrolling adults with microbiologically confirmed MDR-TB. Patients received either standard MDR-TB chemotherapy alone (control group) or in combination with Yuehua Decoction (Yuehua group) based on treatment preference. The primary outcome was HRQoL at 6 months, assessed using the St. George's Respiratory Questionnaire (SGRQ). Between-group differences were analyzed using multivariable linear regression adjusting for baseline SGRQ and other clinically relevant covariates. Secondary outcomes included sputum culture conversion and treatment-related adverse events. Results: Seventy-one patients were included (Yuehua group, Conclusion: In this preliminary prospective cohort, adjunctive Yuehua Decoction was associated with improved HRQoL without increasing treatment-related toxicity among patients undergoing MDR-TB chemotherapy. These findings support Yuehua Decoction as a potential host-directed adjunct, but confirmation in larger randomized controlled trials is needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.